Prostate-specificmembrane antigen (PSMA)-targeted radionuclide therapy is a well-developedapproach for prostate cancer treatment; however, current small moleculeand antibody carriers for molecular radiotherapy each have drawbacksin their biodistribution and consequent side effects as highlightedin current clinical trials. The gene discussed is FOLH1; the disease is prostate carcinoma.